Top 10 Antibody Cocktail Companies in World

“Global Antibody Cocktail Market: Growth, Outlook, and Competitive Analysis, 2018 – 2030” is the most recent market study released by Credence Research, Inc. The global antibody cocktail market had revenue of about USD 2.2 billion in 2022, and it is predicted to increase at a CAGR of more than 10.9% from 2018 to 2030, reaching about USD 4.5 billion.

Market Overview

The cocktail is made up of two monoclonal antibodies, which are proteins that are created in a laboratory to act like the natural antibodies that are found in the immune system. They bind to non-overlapping portions of the SARS-CoV-2 spike protein in the key location where the virus latches onto human cells. This allows them to prevent the virus from infecting human cells. This stops the production of new virus particles, which stops the spread of infection to other cells. Compared to the use of only one antibody, the use of two antibodies significantly reduces the likelihood that drug-resistant viral variants would emerge. It is anticipated that the rising incidence of several infectious illnesses, particularly COVID-19, will be a primary factor in the development of the market during the course of the period covered by the projection. The Coronavirus (COVID-19) dashboard of the World Health Organization was updated on February 8, 2022, and it indicated that the coronavirus was responsible for more than 396,558,014 instances of illness and 5,745,032 deaths (COVID-19). Due to the rising prevalence of diseases such as cancer and the subsequent efforts made by major companies and scientists to discover a treatment option that is both safe and effective in combating the condition, it is anticipated that the global market for antibody cocktails will expand over the course of the period under consideration. According to a study by the World Health Organization on February 3, 2022, cancer was the leading cause of death worldwide. This disease was responsible for around 10 million deaths in 2020, corresponding to almost one in six deaths throughout the globe. As a result of regulatory authorities progressively allowing items for antibody cocktail therapy, it is anticipated that the market for antibody cocktails will expand throughout the period covered by this estimate.

Company Profile

1. Cipla Inc.

Cipla continually ensures that people in need have access to high-quality, low-cost medicines. As a result, healthcare professionals and patients worldwide have trusted them over the past eight decades. Cipla has been constructed from the ground up on the foundation of care. Caring For Life has always been and will always be their guiding aim. Driven by the same goal, they have expanded our footprint to 80+ countries, offering over 1,500 medications in 50+ dosage forms across diverse therapeutic areas. They are expanding our footprint in important emerging regions such as India, South Africa, and the United States to make healthcare more accessible globally.

2. Hoffmann-La Roche Ltd

Roche has grown into one of the world’s largest biotech businesses, a leading provider of in-vitro diagnostics, and a global supplier of transformational new solutions across major disease areas over its 125-year history. Their dedication to our workers, partners, stakeholders, and, most importantly, their patients has not wavered since the beginning of our adventure. Roche’s success stems from its organizational structure, which is science-driven and intended for innovation. They encourage a variety of scientific perspectives and welcome new ideas. They are well-positioned to produce medical breakthroughs for patients and society by combining this with the seamless integration of our strengths in Roche Pharma and Roche Diagnostics.

3. Regeneron Pharmaceuticals Inc.

Regeneron is a renowned biotechnology business that develops and commercializes life-changing medications for patients with critical diseases. Regeneron’s unique capacity to regularly and consistently transfer science into medicine has resulted in multiple FDA-approved therapies and product candidates in development, almost all homegrown in Regeneron’s laboratories. The drugs and pipeline of Regeneron are intended to aid patients suffering from eye illnesses, allergy and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic problems, infectious diseases, and uncommon diseases. The Regeneron Genetics Center® is leading one of the largest genetics sequencing efforts in the world, and other patented VelociSuite® technologies, such as VelocImmune®, are helping to speed up and enhance the conventional drug development process.

4. Zydus Cadila

Zydus Lifesciences Limited, originally Cadila Healthcare Limited, is an Indian multinational pharmaceutical business based in Ahmedabad that mostly manufactures generic pharmaceuticals. In 2020, the company was rated 100th on the Fortune India 500 list. Ramanbhai Patel (1925-2001), a lecturer at the L.M. Faculty of Pharmacy, and his business partner Indravadan Modi launched Cadila in 1952. Over the next four decades, it grew into a well-known pharmaceutical corporation. Zydus Cadila develops and manufactures a wide range of pharmaceuticals, diagnostics, herbal items, skincare products, and over-the-counter (OTC) products from twenty-five pharmaceutical manufacturing operations in India. After signing a voluntary license agreement with Gilead in late 2015, the company began producing generics for HEP-C.

5. AstraZeneca

AstraZeneca plc is a multinational pharmaceutical and biotechnology business based in the United Kingdom, and Sweden has its headquarters in Cambridge, UK, at the Cambridge Biomedical Campus. Its product portfolio includes treatments for important cancer, cardiology, gastrointestinal, infection, neurology, respiratory, and inflammation disorders. It was involved in the development of the Oxford-AstraZeneca COVID-19 vaccine. In 1999, the Swedish Astra AB and the British Zeneca Group merged to form the firm. Since the merger, it has become one of the world’s largest pharmaceutical businesses and has made numerous corporate acquisitions, including Cambridge Antibody Technologies, MedImmune, Spirogen, and Definiens. It concentrates its research and development in three strategic locations: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, USA.

6. Aridis Pharmaceuticals Inc.

Aridis discovers and develops highly differentiated medication candidates to prevent and treat life-threatening infectious diseases, overcoming the threat of AMR and viral pandemics, using therapeutic monoclonal antibodies and new anti-infectives to improve current treatment standards. PEX and MabIgX®, the company’s unique technological platforms, may swiftly identify human-derived monoclonal antibodies for various infectious disorders and use them as therapeutic agents that optimally eliminate invading pathogens. Aridis is led by a world-class team of scientists, senior executives, and industry experts with vast expertise in developing anti-infective immunotherapies for patients suffering from serious respiratory infections.

7. Immunome Inc.

Immunome was developed to advance antibody-based medication discovery and development. Their patented antibody Discovery Engine finds novel therapeutic antibodies and their antigen targets using the most highly educated components of B cells from patients who have learned to fight their disease. The Immunome technology enables us to go directly from human B cell interrogation to massive numbers of antibodies required for function-based screening. They have examined over 150 patient samples and generated over 250,000 hybridomas from individuals with diverse malignancies and infectious illnesses. Immunome’s mission is to become a premier biopharmaceutical firm focusing on discovering and developing breakthrough antibody treatments for areas of high unmet medical need, with a growing pipeline of novel targets.

8. Celltrion Healthcare Co., Ltd.

Celltrion Healthcare negotiated a global copyright deal with Celltrion when the biosimilar business was in its infancy, based on its faith in the success of biosimilars. Remsima ®, the world’s first antibody biosimilar, was launched in Europe in 2013, leading the global pharmaceutical industry and significantly publicizing the potential of biosimilars worldwide. Celltrion Healthcare achieved 1 trillion won in cumulative Remsima ® exports in 2016, a feat that will go down in the history of domestic biopharmaceuticals. Furthermore, they demonstrated the global market success of biosimilars by releasing Remsima ® (Inflectra ®) in the United States, the world’s largest pharmaceutical market, and Truxima ®, the world’s first antibody biosimilar anti-cancer medication, in Europe.

9. Eli Lily & Company

With operations throughout 18 nations, Eli Lilly and Company is an American pharmaceutical firm with its main office in Indianapolis, Indiana. Over 125 nations sell its products. The business was established in 1876 and is named after Colonel Eli Lilly, a scientist, and American Civil War soldier. By 2022, Lilly will be best known for its antipsychotic drug Zyprexa (olanzapine) and its clinical depression drugs Prozac (fluoxetine), Cymbalta (duloxetine), and Trulicity (dulaglutide), though its diabetes medications Humalog (insulin lispro), and Trulicity (dulaglutide), will generate the majority of its revenue (2014). Among Lilly’s accomplishments is becoming the first business to mass-produce the Jonas Salk-developed polio vaccine and insulin. It was one of the first pharmaceutical businesses to use recombinant DNA to generate human insulin, including Humulin (insulin medicine), Humalog (insulin lispro), and Basaglar, the first biosimilar insulin product to receive US approval (insulin glargine).